Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
generic:
mechanism:
Monoamine releasing agent (8) ·
Dopamine/norepinephrine reuptake inhibitor (5) ·
NMDA antagonist (3) ·
Cathinone analogue; monoamine reuptake inhibitor (2) ·
Dopamine and norepinephrine reuptake inhibitor (2) ·
NMDA antagonist; sigma receptor agonist (2) ·
Norepinephrine–dopamine reuptake inhibitor (2)
None (62) ·
0.5–1 oz (10–30 g) ground for psychoactive effect; far smaller for culinary use (1) ·
Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)
Showing below up to 64 results in range #1 to #64.


